Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04071236
Title Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

prostate cancer


Peposertib + Radium Ra 223 dichloride

Radium Ra 223 dichloride

Avelumab + Peposertib + Radium Ra 223 dichloride

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.